Healthcare Use According to Breast Cancer Subtype in Early Breast Cancer: A Patient-Level Data Analysis in Taiwan
Speaker(s)
Chou HH1, Kuo WL1, Yang CK1, Peng MT1, Woo A2, Kuo YC3, Huang H3, Lin Q4, Li A5, Chen SC1
1Linkou Chang Gung Memorial Hospital, Taoyuan City, Taoyuan, Taiwan, 2Oracle Life Sciences, Singapore, 05, Singapore, 3Oracle Life Sciences, Taipei, Taiwan, 4Oracle Life Sciences, Taipei, TPE, Taiwan, 5Cerner Enviza, Shanghai, 31, China
Presentation Documents
OBJECTIVES: This study explored the relationship of healthcare use (HCU) within the first 2 years after diagnosis of early breast cancer (BC) subtype in Taiwan, using patient-level data.
METHODS: This non-interventional study used retrospective clinical patient chart data from early BC patients diagnosed between 2018-2021 from Linkou Chang-Gung Memorial Hospital, Taiwan. Data pertained to patient profiles, treatment patterns, and healthcare use within first 2 years post-diagnosis. Adjusted odds-ratio (aOR) and 95% confidence interval (CI) were computed using logistic regression to quantify the association between tumor subtype (human epidermal growth factor-2-positive [HER2+], HER2-negative/hormone receptor-positive [HER2-/HR+], triple-negative breast cancer [TNBC]), and HCU.
RESULTS: Data of 1719 early BC patients were analyzed, with 67.4% having HER2-/HR+ subtype (HER2+: 23.7%; TNBC: 8.9%). A higher proportion of early BC patients had stage 2 cancer (HER2-/HR+: 48.5%; HER2+: 59.2%; TNBC: 61.4%), lymph node negative (71.4%; 56.5%; 61.4%), had breast conserving surgery (68.9%; 60.2%; 69.3%), did not have neoadjuvant treatment (82.3%; 60.9%; 52.3%) and had adjuvant treatment (95.8%; 92.9%; 72.6%). Compared with HER2-/HR+ patients, HER2+ and TNBC subtypes were more likely to have neoadjuvant treatment (aOR [95% CI], HER2+: 2.51 [1.89-3.33]; TNBC: 4.78 [3.17-7.20]), ≥37 outpatient visits (2.39 [1.85-3.10]; 2.00 [1.36-2.94]), ≥8 hospitalizations (3.53 [2.67-4.65]; 4.06 [2.67-6.18]), and longer hospitalization stay of ≥14 days (3.61 [2.77-4.71]; 2.29 [1.52-3.44]); but were less likely to have adjuvant treatment (0.56 [0.34-0.91]; 0.12 [0.07-0.19]) within 2-years’ post-diagnosis (all p<0.05). When comparing healthcare use, HER2+ was more likely than TNBC to have higher outpatient and emergency department visits and longer hospitalization stays.
CONCLUSIONS: The HCU in early BC care within the first 2-years’ post-diagnosis was mainly driven by the tumor subtype with higher utilization associated with HER2+. These data implied a need for efforts to address the potential healthcare burden for early breast cancer in Taiwan.
Code
PCR25
Topic
Epidemiology & Public Health, Patient-Centered Research, Study Approaches
Topic Subcategory
Electronic Medical & Health Records, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology